Retirement Systems of Alabama increased its stake in Arthur J. Gallagher & Co. (NYSE:AJG – Free Report) by 13.2% in the 3rd quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 201,076 shares of the financial services provider’s stock after acquiring an additional 23,433 shares during the [...]
Financial markets are constantly explained but rarely understood. Every price movement is accompanied by a narrative: inflation fears, growth optimism, geopolitical tension, earnings surprises, technological breakthroughs
Twist Bioscience represents synthetic DNA platform technology with AI-enabled drug discovery traction and improving gross margins, though profitability timeline uncertainty pressures valuation despite 20% revenue growth.
November 14, 2025 was a lighter earnings day dominated by Twist Bioscience's synthetic DNA platform story, alongside smaller cap utilities, clinical biotech, lithium producers, and crypto miners—a diverse but lower-profile Friday close-out to the quarterly reporting cycle.
A clear-eyed look at when killing debt brings real relief and when letting money grow elsewhere quietly works harder over time. Read Full Article →
